Coeptis to List Z Squared on Nasdaq as ZSQR

Coeptis Therapeutics Holdings announced that Nasdaq approved, subject to customary conditions and the closing of its pending merger, the listing of the post-merger company’s common stock on the Nasdaq Global Market under ticker symbol ZSQR.

The listing is expected to become effective upon closing of the proposed merger between Coeptis and Z Squared, Inc., under which Z Squared will become a wholly owned subsidiary of Coeptis and the company will change its corporate name to Z Squared Inc. The transaction is expected to close in Q2 2026, following prior satisfaction of conditions including Form S-4 effectiveness and shareholder approval on January 30, 2026.